IMKASID 2025

PE8-01 Poster Exhibition
View : 6
Efficacy and Safety of Obefazimod in UC Patients at Week 48 of an Open-label Maintenance Study among Clinical Non-responders at Week 8 of the Phase 2b Induction Trial

Presenting Author : Raja Atreya (University Hospital Erlangen, Germany)
PE8-02 Poster Exhibition
View : 9
Efficacy and Safety of Etrasimod Induction Therapy in Asia Patients with Moderately to Severely Active Ulcerative Colitis: Results from the 12-week Induction Period of Phase 3 China Registrational Study (ES101002)

Presenting Author : Tae-Oh Kim (Inje University Haeundae Paik Hospital, Korea)
PE8-03 Poster Exhibition
View : 9
Measurement of IL-6, IL-6Ra and GP130 in Gastrointestinal Behcet Disease Mucosal Biopsies

Presenting Author : Philippe Pinton (Ferring Pharmaceuticals, Denmark)
PE8-04 Poster Exhibition
View : 7
Improvements in Inflammatory Bowel Disease Questionnaire Items Fatigue, Depression, Anxiety, and Bowel Urgency in Patients with Crohn's Disease Treated With Upadacitinib in Phase 3 Trials

Presenting Author : Scott Choi (AbbVie Korea, Korea)
PE8-05 Poster Exhibition
View : 1
Improvement in Health-Related Quality of Life in Adults with Recurrent Clostridioides difficile Infection after Fecal Microbiota, Live-jslm (RBX2660) Administration by Colonoscopy

Presenting Author : Philippe Pinton (Ferring Pharmaceuticals, A/S, Denmark)
PE8-06 Poster Exhibition
View : 16
Budget lmpact Analysis to Assess Potential Cost Savings from the lntroduction of Ustekinumab Biosimilars in Germany, the UK, and Sweden

Presenting Author : Joungyoun Noh (Samsung Bioepis, Korea)
PE8-07 Poster Exhibition
View : 9
TUSCANY-2: A Dose-Ranging Phase IIb Study Evaluating Efficacy and Safety of RO7790121, an Antibody Against Tumor Necrosis Factor-like Ligand 1A (Anti-TL1A) in Adults with Moderately to Severely Active Ulcerative Colitis

Presenting Author : Eun Soo Kim (School of Medicine, Kyungpook National University, Korea)
PE8-08 Poster Exhibition
View : 7
Efficacy and Safety of Upadacitinib after 3 years of Treatment in Patients with Moderately to Severely Active Ulcerative Colitis: Interim Long-term Data from the Phase 3 Open-label Extension Study

Presenting Author : Scott Choi (AbbVie Korea, Korea)
PE8-09 Poster Exhibition
View : 6
Corticosteroid-free Clinical and Endoscopic Response of Risankizumab Through Week 144 in Patients With Moderately to Severely Active Crohn’s Disease: A Post hoc Analysis from the fortify Long-term Extension Substudy

Presenting Author : Scott Choi (AbbVie Korea, Korea)
PE8-10 Poster Exhibition
View : 10
Support Program for Patients Receiving Imraldi or Benepali Therapy for Immune-mediated Inflammatory Disorders: 12-Month Persistence

Presenting Author : Andrew Clark (Biogen Idec Ltd., United Kingdom)
PE8-11 Poster Exhibition
View : 9
Persistence of Treatment Effect in Patients with Ulcerative Colitis and Crohn’s Disease: Long-term Results from the Visible Ole Study

Presenting Author : Dong Il Park (Kangbuk Samsung Hospital, School of Medicine, Sungkyunkwan University, Korea)
PE8-12 Poster Exhibition
View : 2
Management of Recurrent Clostridioides Difficile Infection: A Systematic Literature Review to Assess the Feasibility of Indirect Treatment Comparisons

Presenting Author : Philippe Pinton (Ferring Pharmaceuticals, A/S, Denmark)
PE8-13 Poster Exhibition
View : 14
Real-world Safety and Effectiveness of SB5 (adalimumab biosimilar) in South Korea: A Real-world Post-marketing Surveillance Interim Analysis Data

Presenting Author : Hawon Jeong (Samsung Bioepis, Korea)